Determination of the activation spectrum of aluminium phthalocyanine chloride against cultured meningioma cells using a tunable laser

Journal of Clinical Neuroscience

Volumn 3, Issue 3, 1996, Pages 252-256

  Wilson, Andrew C ^a   Malham, Gregory M ^b   Thomsen, Raewyn J ^c   Harvey, John D ^a   Baguley, Bruce C ^d  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

^c Department of Pathology ^*  (New Zealand)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Absorption; Activation spectrum; Culture; Laser; Meningioma; Photodynamic therapy

Indexed keywords

EID: 0343844546     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0967-5868(96)90060-0     Document Type: Article

References (20)

1. Lin C-W. Photodynamic therapy of malignant tumors-recent developments. Cancer Cells 1991; 3: 437-44.
2. Kessel D. Photodynamic therapy and neoplastic disease. Oncol Res 1992; 4: 219-25.
3. Chan WS, Marshall JF, Svensen R, et al. Effect of sulfonation on the cell and tissue distribution of the photosensitizer aluminum phthalocyanine. Cancer Res 1990; 50: 4533-8.
4. Rosenthal I. Phthalocyanines as photodynamic sensitizers. Photochem Photobiol 1991; 53: 859-70.
5. Ben-Hur E, Rosenthal I. The phthalocyanines: a new class of mammalian cells photosensitizers with a potential for cancer phototherapy. Int J Radiat Biol 1985; 47: 145-147.
6. Malham GM, Thomsen RJ, Finlay GJ, et al. Subcellular distribution and photocytotoxicity of aluminium phthalocyanines and haematoporphyrin derivative in cultured human meningioma cells. Br J Neurosurg 1996; 10: 51-57.
7. Demtröder W. Laser Spectroscopy. Berlin: Springer Verlag, 1981.
8. Dougherty T. Yearly Review. Photodynamic Therapy. Photochem Photobiol 1993; 58: 895-900.
9. Abernathey CD, Anderson RE, Kooistra KL, et al. Activity of phthalocyanine photosensitizers against human glioblastoma in vitro. Neurosurgery 1987; 21: 468-73.
10. Rey J, Pestana A, Bello M. Cytogenetics and molecular genetics of nervous system tumours. Oncol Res 1992; 4: 321-31.
11. Mayberg MR, Symon L. Meningiomas of the clivus and apical petrous bone. Report of 35 cases. J Neurosurg 1986; 65: 160-7.
12. Black PM. Brain tumors (second of two parts). New England J Med 1991; 324: 22: 1555-64.
13. Al-Mefty O, Routh A, Smith RR. The long term side effects of radiation therapy for benign brain tumours in adults. J Neurosurg 1990; 73: 502-12.
14. Schrell UMH, Fahlbusch R. Hormonal manipulation of cerebral meningiomas. In: Al-Mefty O, ed. Meningiomas. New York: Raven Press, 1991: 273-83.
15. Malham GM, Thomsen RJ, Synek BJ, et al. Diagnostic markers demonstrating successful culture of human meningioma cells. Journal of Clinical Neuroscience 1995; 2: 59-63.
16. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 1983; 65: 55-63.
17. Finlay GJ, Wilson WR, Baguley BC. Comparison of in vitro activity of cytotoxic drugs toward human carcinoma and leukaemia cell lines. Eur J Cancer Clin Oncol 1986; 22: 655-62.
18. Spikes JD. Phthalocyanines as photosensitisers in biological systems and for the photodynamic therapy of tumors. Photochem Photobiol 1986; 43: 691-9.
19. Berg K, Bommer JC, Moan J. Evaluation of sulfonated aluminum phthalocyanines for use in photochemotherapy. A study on the relative efficiencies of photoinactivation. Photochem Photobiol 1989; 49: 587-94.
20. Moan J, Peng Q, Evensen F, et al. Photosensitizing efficiencies, tumor- and cellular uptake of different photosensitizing drugs relevant for photodynamic therapy of cancer. Photochem Photobiol 1987; 46: 713-21.